ArticleTranslational cancer research2026
Curcumin inhibits the proliferation of diffuse large B-cell lymphoma by inducing ferroptosis via the ACSL4-SAT1-GPX4 axis.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Curcumin exhibits anti-inflammatory, antioxidant, and anti-tumor effects. However, its specific mechanisms of action in diffuse large B-cell lymphoma (DLBCL) remain unclear. This study aims to investigate the inhibitory effect of curcumin on DLBCL cells and to elucidate the underlying molecular mechanisms, with a specific focus on its role in regulating the ferroptosis pathway. Methods: The anti-proliferative effect of curcumin on human DLBCL cell lines (SU-DHL-2 and OCI-LY7) was assessed using the Cell Counting Kit-8 (CCK-8) assay. Transcriptome sequencing and bioinformatics analysis were performed on curcumin-treated OCI-LY7 cells to identify potential mechanisms. Ferroptosis-related indicators were evaluated, including lipid reactive oxygen species (ROS) levels (BODIPY™ C11 probe), mitochondrial membrane potential (JC-1 staining), intracellular Fe Results: Curcumin significantly inhibited the proliferation of SU-DHL-2 and OCI-LY7 cells in a concentration- and time-dependent manner. Transcriptome analysis revealed significant enrichment of differentially expressed genes in the ferroptosis pathway. Curcumin treatment led to a concentration-dependent upregulation of ACSL4 and SAT1 protein expression and downregulation of GPX4. Functionally, curcumin induced characteristic features of ferroptosis: accumulation of lipid ROS and intracellular Fe Conclusions: Curcumin inhibits the proliferation of DLBCL cells by activating the ferroptosis-related pathway, likely through modulating the ACSL4-SAT1-GPX4 axis. These findings provide a novel mechanistic insight into the anti-tumor activity of curcumin for DLBCL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.